Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RESULTS FROM AN INTERIM ANALYSIS IN THE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC LMS PATIENTS REMAIN ON TRACK FOR 4Q 2025 EXPECT TO PRESENT INTERIM ANALYSIS FROM APPROXIMATELY 25 SIX-MONTH EVALUABLE BCG-UNRESPONSIVE NMIBC PATIENTS IN THE ONGOING ADVANCED-2 TRIAL IN 1Q 2026 DOSING OF FIRST PATIENT IN THRIVE-3 REGISTRATIONAL TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS DEPENDENT ON PARENTERAL SUPPORT NOW EXPECTED BY YEAR-END 2025 CASH, CASH EQUIVALENTS AND INVESTMENTS OFAPPROXIMATELY$134MILLIONAS OFSEPTEMBER 30, 2025, EXPECTED TO SUPPORT PLANNED OPERATIONS INTO MID-2027 NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. WE HAVE MADE IMPORTANT ADVANCEMENTS ACROSS OUR CLINICAL PROGRAMS THIS YEAR, AND WITH MANY SIGNIFICANT MILESTONES IN THE NEAR FUTURE, WE REMAIN FOCUSED ON DISCIPLINED EXECUTION ACROSS OUR PIPELINE OF TRANSFORMATIVE THERAPIES FOR PATIENTS WITH CANCER AND RARE DISEASES, SAIDJESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OFPROTARA THERAPEUTICS.

PROTARA THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NOV. 04, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT IT HAS BEEN NAMED A BIOSPACE 2026 BEST PLACE TO WORK. PROTARA IS THRILLED TO BE RECOGNIZED AS ONE OF THE MOST SOUGHT-AFTER BIOTECH EMPLOYERS IN THE LIFE SCIENCES COMMUNITY, SAID JESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OF PROTARA THERAPEUTICS.

PROTARA THERAPEUTICS NAMED A 2026 BEST PLACES TO WORK WINNER BY BIOSPACE

NEW YORK, OCT. 01, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE RECENT GRANTS OF INDUCEMENT NON-QUALIFIED STOCK OPTIONS AND RESTRICTED STOCK UNITS (RSUS) TO ONE NEWLY-HIRED EMPLOYEE.

Protara Therapeutics, Inc.

TARA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Protara Therapeutics, Inc.

TARA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TARA